Stock 4157 TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials TaiGen Biopharmaceuticals Holdings Limited

Equities

4157

KYG866171005

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
15.4 TWD -0.65% Intraday chart for TaiGen Biopharmaceuticals Holdings Limited -6.38% +1.32%
Mar. 15 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TaiGen Biopharmaceuticals Holdings Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 12,185 13,190 16,380 11,039 11,505 10,911
Enterprise Value (EV) 1 11,403 12,619 16,066 10,168 10,645 9,948
P/E ratio -35.5 x -44.6 x -40.5 x 14.3 x -48.5 x 80 x
Yield - - - - - -
Capitalization / Revenue 411 x 649 x 699 x 8.53 x 318 x 88.6 x
EV / Revenue 385 x 621 x 686 x 7.85 x 294 x 80.8 x
EV / EBITDA -45.9 x -47.6 x -54.4 x 11.2 x -39.8 x -60.4 x
EV / FCF -58.7 x -65.3 x -143 x 27.8 x 187 x -118 x
FCF Yield -1.7% -1.53% -0.7% 3.6% 0.54% -0.85%
Price to Book 11.1 x 16.2 x 37 x 8.81 x 11.9 x 9.75 x
Nbr of stocks (in thousands) 716,760 716,840 716,844 716,844 716,844 717,844
Reference price 2 17.00 18.40 22.85 15.40 16.05 15.20
Announcement Date 3/29/19 3/25/20 3/29/21 3/31/22 3/23/23 3/15/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 29.62 20.31 23.42 1,295 36.23 123.1
EBITDA 1 -248.2 -264.9 -295.5 909.9 -267.5 -164.6
EBIT 1 -258.4 -277.1 -307.3 899.5 -277.7 -174.7
Operating Margin -872.43% -1,364.25% -1,312.1% 69.48% -766.41% -141.88%
Earnings before Tax (EBT) 1 -343.2 -290.2 -406.9 876 -229.8 143.5
Net income 1 -343.2 -295.7 -404.8 775.6 -237.2 136.7
Net margin -1,158.79% -1,455.57% -1,728.37% 59.92% -654.61% 111.04%
EPS 2 -0.4788 -0.4125 -0.5647 1.080 -0.3308 0.1900
Free Cash Flow 1 -194.3 -193.3 -112 366.4 57.08 -84.51
FCF margin -656% -951.38% -478.11% 28.3% 157.54% -68.63%
FCF Conversion (EBITDA) - - - 40.27% - -
FCF Conversion (Net income) - - - 47.24% - -
Dividend per Share - - - - - -
Announcement Date 3/29/19 3/25/20 3/29/21 3/31/22 3/23/23 3/15/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 782 571 314 871 860 963
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -194 -193 -112 366 57.1 -84.5
ROE (net income / shareholders' equity) -27.3% -31% -64.4% 91.5% -21.3% 13.1%
ROA (Net income/ Total Assets) -11.9% -16.2% -25.6% 57.7% -14.2% -9.59%
Assets 1 2,879 1,821 1,583 1,345 1,667 -1,426
Book Value Per Share 2 1.530 1.140 0.6200 1.750 1.350 1.560
Cash Flow per Share 2 0.2100 0.1900 0.0800 0.5100 0.3400 0.5200
Capex 1 21.6 3.87 5.46 10.2 3.39 3.89
Capex / Sales 73.03% 19.05% 23.32% 0.79% 9.36% 3.16%
Announcement Date 3/29/19 3/25/20 3/29/21 3/31/22 3/23/23 3/15/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
TAIGEN BIOPHARMACEUTICALS HOLDINGS LIMITED Stock TaiGen Biopharmaceuticals Holdings Limited
+1.32% 339M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 4157 Stock
  4. Financials TaiGen Biopharmaceuticals Holdings Limited